Literature DB >> 24183588

Towards tropomyosin-related kinase B (TrkB) receptor ligands for brain imaging with PET: radiosynthesis and evaluation of 2-(4-[(18)F]fluorophenyl)-7,8-dihydroxy-4H-chromen-4-one and 2-(4-([N-methyl-(11)C]-dimethylamino)phenyl)-7,8-dihydroxy-4H-chromen-4-one.

Vadim Bernard-Gauthier1, Mehdi Boudjemeline, Pedro Rosa-Neto, Alexander Thiel, Ralf Schirrmacher.   

Abstract

The interaction of tropomyosin-related kinase B (TrkB) with the cognate ligand brain-derived neurotrophic factor (BDNF) mediates fundamental pathways in the development of the nervous system. TrkB signaling alterations are linked to numerous neurodegenerative diseases and conditions. Herein we report the synthesis, biological evaluation and radiosynthesis of the first TrkB radioligands based on the recently identified 7,8-dihydroxyflavone chemotype. 2-(4-[(18)F]fluorophenyl)-7,8-dihydroxy-4H-chromen-4-one ([(18)F]10b) was synthesized in high radiochemical yields via an efficient SNAr radiofluorination involving a para-Michael acceptor substituted aryl followed by BBr3-promoted double demethylation. Selective N-[(11)C]methylation afforded 2-(4-([N-methyl-(11)C]-dimethylamino)phenyl)-7,8-dihydroxy-4H-chromen-4-one ([(11)C]10c) from the fully deprotected catechol-bearing normethyl precursor 13 with [(11)C]MeOTf. In vitro autoradiography of [(18)F]10b with transverse rat brain sections revealed high specific binding in the cortex, striatum, hippocampus and thalamus in accordance with expected TrkB distribution. Blockade experiments with both 7,8-dihydroxyflavone (1a) and TrkB cognate ligand, BDNF, led to decreases of 80% and 85% of radioligand binding strongly supporting the hypothesis that 7,8-dihydroxyflavones exert their effect on TrkB phosphorylation via direct TrkB extracellular domain (ECD) binding. Positron emission tomography (PET) studies revealed that [(18)F]10b and [(11)C]10c brain uptake is minimal and that they are rapidly eliminated from the plasma (effective plasma half-life 5-10 min) via hepatic secretion. Nevertheless, the high specific binding and TrkB specificity derived from in vitro experiments suggests that the 7,8-disubstituted flavone chemotype represents a promising scaffold for the development of TrkB radiotracers for PET.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  7,8-Dihydroxyflavone; Carbon-11; Fluorine-18; Positron emission tomography; Radiochemistry; Tropomyosin-related kinases B receptor

Mesh:

Substances:

Year:  2013        PMID: 24183588     DOI: 10.1016/j.bmc.2013.10.012

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  5 in total

1.  7,8-Dihydroxyflavone facilitates the action exercise to restore plasticity and functionality: Implications for early brain trauma recovery.

Authors:  Gokul Krishna; Rahul Agrawal; Yumei Zhuang; Zhe Ying; Afshin Paydar; Neil G Harris; Luiz Fernando F Royes; Fernando Gomez-Pinilla
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-03-14       Impact factor: 5.187

2.  Biochemical and biophysical investigation of the brain-derived neurotrophic factor mimetic 7,8-dihydroxyflavone in the binding and activation of the TrkB receptor.

Authors:  Xia Liu; Obiamaka Obianyo; Chi Bun Chan; Junjian Huang; Shenghui Xue; Jenny J Yang; Fanxing Zeng; Mark Goodman; Keqiang Ye
Journal:  J Biol Chem       Date:  2014-08-20       Impact factor: 5.157

3.  An agent for optical imaging of TrkC-expressing, breast cancer.

Authors:  Anyanee Kamkaew; Feng Li; Zheng Li; Kevin Burgess
Journal:  Medchemcomm       Date:  2017-09-14       Impact factor: 3.597

Review 4.  Therapeutic potential of brain-derived neurotrophic factor (BDNF) and a small molecular mimics of BDNF for traumatic brain injury.

Authors:  Mary Wurzelmann; Jennifer Romeika; Dong Sun
Journal:  Neural Regen Res       Date:  2017-01       Impact factor: 5.135

Review 5.  Clinical imaging in regenerative medicine.

Authors:  Anna V Naumova; Michel Modo; Anna Moore; Charles E Murry; Joseph A Frank
Journal:  Nat Biotechnol       Date:  2014-08       Impact factor: 68.164

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.